The rational for this strategy was, besides adding to information about the human NP phenotype, to identify potential NP-specific cell surface markers, which could be used to target specific cells with nanoparticles and, thereby, systemically delivering potential therapies to the NP cells.
In light of the lack of clearly demonstrated benefits of PN, clinicians considering its early administration should realize that, besides the purchase cost of PN itself, this strategy will, above all, generate important expenses mediated by clinical complications.
This strategy would have the advantage that, besides confirming the diagnosis, the added report would draw the physician's attention to the potential problem.
Implementation of this strategy will have positive technological effects since, besides the improvement in strength, a definite correlation between uniform elongation and work-hardening capacity was clearly demonstrated.
Lastly, our findings add to a growing body of evidence in support of this strategy for immunogen design for poorly immunogenic epitopes besides the MPR of HIV-1's transmembrane envelope protein.
